CORDIS · 643809 · H2020
ADIPOA2 Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis
Coordinator: UNIVERSITY OF GALWAY (IE)
Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to prevent disease progression. Currently, OA is designated the 11th highest contributor (of 291 diseases) of global disability. In the absence of effective treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential candidates to overcome this clinical short-coming. Autologous adipose-derived mesenchymal stromal cells (ASCs) are attractive for cellular therapy given the abundance of tissue, high frequency of MSCs a…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €6.0M awarded to the consortium. The project runs over approximately 5 years from 2015-01-01 to 2019-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from IE
see all →- MSCA4Ukraine — MSCA4Ukraine101101923 · HORIZON · €35.0M
- WaterLANDS — Water-based solutions for carbon storage, people and wilderness101036484 · H2020 · €23.1M
- INFRACHIP — European Research Infrastructure on Semiconductor Chips101131822 · HORIZON · €14.5M
- PRIMES — PRIMES: Protein interaction machines in oncogenic EGF receptor signalling278568 · FP7 · €12.0M
- NAMDIATREAM — NANOTECHNOLOGICAL TOOLKITS FOR MULTI-MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING246479 · FP7 · €12.0M
- REALLOCATE — Rethinking the dEsign of streets And pubLic spaces to Leverage the mOdal shift to Climate-friendly Active Transport Everywhere101103924 · HORIZON · €12.0M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M toward a total project budget of €6.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-PHC-2014-2015.
- Who coordinates the project?
- The project is coordinated by UNIVERSITY OF GALWAY (IE).
- What is the project timeline?
- The project runs from 2015-01-01 to 2019-12-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 643809.